
INDUSTRY OVERVIEW

The information and statistics set out in this section and other sections of this document were extracted from a report prepared by Frost & Sullivan, which was commissioned by us, and from various official government publications and other publicly available publications. We engaged Frost & Sullivan to prepare the Frost & Sullivan Report, an independent industry report, in connection with the [REDACTED]. The information from official government sources has not been independently verified by us or any other parties involved in the [REDACTED], or any of our or their respective directors, senior management, representatives, advisers or any other persons involved in the [REDACTED], and no representation is given as to its accuracy, fairness and completeness. For a discussion of the risks relating to our industry, see “Risk Factors”. Our Directors confirm that, after making reasonable enquiries, there is no adverse change in the market information since the date of the Frost & Sullivan Report that would qualify, contradict or have a material impact on the information in this section.

GLOBAL MEDICAL DEVICE MARKETS

Overview of Medical Device Market

The medical device market may be classified from two principal perspectives: by product characteristics, including medical equipment and medical consumables, and by clinical application, including in vitro diagnostics (IVD), patient monitoring and life support (PMLS), medical imaging, minimally invasive surgery, minimally invasive intervention, animal medical devices and other emerging segments.

Market Size and Growth Trends

The Global Medical Device Market


The global medical device market increased from US\$456.6 billion in 2020 to US\$623.0 billion in 2024, representing a CAGR of 8.1% from 2020 to 2024, and is expected to reach US\$869.7 billion in 2030 and US\$1,157.6 billion in 2035, representing CAGRs of 6.0% from 2025 to 2030 and 5.7% from 2031 to 2035, respectively.

Within the global medical consumable segment, high-value interventional and electrophysiology consumables are expected to achieve above-market growth due to continuous innovation and clinical demand. Within the global medical equipment segment, intelligent, connected and minimally invasive devices are forecast to expand rapidly as digitalization, automation and AI-assisted technologies reshape diagnostic and therapeutic workflows.

INDUSTRY OVERVIEW

Global Medical Device Market Size and Forecast, Breakdown by Business Sector, 2020-2035E

Unit: Billion USD
At ex-factory price level




Source: Frost & Sullivan Analysis

China's Medical Device Market

From 2020 to 2024, the market rose from RMB729.8 billion to RMB941.7 billion at a CAGR of 6.6%. It is expected to reach RMB1,326.0 billion in 2030 at a CAGR of 6.4% between 2025 and 2030, and further to RMB1,813.4 billion in 2035 at a CAGR of 6.3% between 2031 and 2035.

China Medical Device Market Size and Forecast, Breakdown by Business Sector, 2020-2035E

Unit: Billion RMB
At ex-factory price level



Source: Frost & Sullivan Analysis

INDUSTRY OVERVIEW

Development Drivers of Medical Device Market

The sustained growth of the global medical device industry is driven by a combination of structural healthcare needs, technological convergence, supportive policy frameworks, and evolving business models. These drivers are reshaping the way healthcare is delivered and accelerating the digital and intelligent transformation of the industry.

- ***Fundamental Demand from Demographics and Rising Health Awareness.*** Population aging, the rising prevalence of chronic diseases and greater health awareness continue to drive demand for diagnostic, monitoring and interventional devices, while higher disposable income, particularly in emerging markets, is supporting broader adoption of advanced diagnostic and therapeutic solutions.
- ***Technological Convergence and the Acceleration of Intelli-Digitalization.*** Advances in AI, automation, device connectivity and hospital IT integration are improving diagnostic accuracy, workflow efficiency and clinical decision-making, while supporting the development of digitalized and intelligent healthcare solutions across imaging, monitoring, IVD and surgical applications.
- ***Policy Support and Healthcare Infrastructure Upgrades.*** Government healthcare reform, capital equipment replacement cycles, hospital capacity expansion and value-based procurement policies continue to support investment in diagnostic, monitoring, imaging and life-support devices, while also promoting adoption of clinically effective and cost-efficient technologies.
- ***Expansion of Emerging Markets and Scalable Solution Deployment.*** Emerging markets continue to be important growth drivers, supported by improving healthcare infrastructure, rising public healthcare investment and growing demand for scalable, solution-based offerings combining devices, consumables, software and services.
- ***Supply Chain Localization and Resilient, Efficiency-Oriented Operations.*** In response to trade disruption and public health events, medical device companies are increasingly strengthening localized R&D, manufacturing and service capabilities, while adopting leaner and more digitalized operations to improve delivery efficiency, resilience and long-term competitiveness.

The medical device industry is being shaped by structural trends including broader penetration into primary care through modular and solution-based offerings, increasing adoption of data connectivity and AI, and continued expansion of minimally invasive and precision therapies.

Meanwhile, the industry faces challenges in scaling products across clinical settings, managing manufacturing and compliance requirements, responding to pricing pressure and supply chain disruption, and overcoming high market entry barriers arising from regulatory requirements, installed base, service capability and clinical evidence expectations.


Regional Market Analysis

Geographically, the medical device market is characterized by varying growth dynamics. While developed markets such as the United States and Europe continue to contribute the largest share, emerging markets are expected to drive the next phase of growth through infrastructure upgrades, expanding healthcare coverage, and increasing demand for accessible, high-quality medical technologies.

INDUSTRY OVERVIEW

Global Medical Device Market Size and Forecast, Breakdown by Region

Unit: Billion USD
At ex-factory price level



Note: The CAGR calculated here excludes the impact of exchange rate fluctuations. Developed markets include North America and EU5; emerging markets include Latin America, Asia Pacific and RoW. China is presented separately.

⁽¹⁾ Comprising of Germany, Italy, France, the United Kingdom, and Spain.

Source: Frost & Sullivan Analysis

The global medical device market reached US\$623.0 billion in 2024, of which developed markets, China and emerging markets accounted for approximately 53.7%, 21.0% and 25.3%, respectively. Emerging markets are expected to grow at a CAGR of 6.7% from 2025 to 2030, compared with 5.5% for developed markets, supported by healthcare infrastructure expansion, public health investment and broader adoption of mid-range products.

In developed markets, demand is mainly driven by technology upgrades and replacement cycles.

In emerging markets, demand is supported by improving healthcare infrastructure and rising public healthcare expenditure. In China, growth continues to be supported by primary healthcare expansion, chronic disease management needs and policies promoting equipment renewal and domestic innovation, despite pricing pressure in certain segments from volume-based procurement.

Competitive Landscape of Global Medical Device Market

According to Frost & Sullivan, based on medical device revenue, the Company’s global ranking improved from 26th in 2020 and 2021 to 24th in 2022, and further to 23rd in 2023 and 2024, representing the fastest improvement among industry participants over the period. In China, the Company has ranked No. 1 among domestic medical device companies for more than five consecutive years and was also the only Chinese company among the top 30 global medical device companies in 2024.

INDUSTRY OVERVIEW

Competitive Landscape of China’s Medical Device Market in Terms of Revenue, 2024

Rank	Company ⁽¹⁾	Revenue	Market Share
		(RMB in Billion)	(%)
1	Company A	36.3	3.9%
2	Company B	26.7	2.8%
3	Mindray	20.3	2.2%
4	Company C	19.1	2.0%
5	Company D	18.9	2.0%

Note:

(1) Company A is a multinational company headquartered in the United States that engages in the research and development, manufacture and sale of a broad range of products in the healthcare field and listed on the New York Stock Exchange.

Company B is a leading global healthcare technology company headquartered in Ireland and listed on the New York Stock Exchange.

Company C is a division of a multinational holding healthcare company headquartered in Switzerland and listed on the SIX Swiss Exchange, offering comprehensive in vitro diagnostics solutions across major disease areas.

Company D is a multinational company headquartered in Germany with specializing in medical technology and medical imaging and listed on the Frankfurt Stock Exchange.

THE IN VITRO DIAGNOSTICS MARKET

Overview

The global IVD market is projected to grow steadily, with varying growth rates across its segments. From 2020 to 2024, the market rose modestly from US\$107.4 billion to US\$126.7 billion, with a CAGR of 4.2%. The market is expected to reach US\$184.7 billion in 2030 at a CAGR of 6.9% between 2025 and 2030, and further to US\$261.5 billion in 2035 at a CAGR of 7.1% between 2031 and 2035. From 2025 to 2030, developed markets are expected to expand from US\$79.7 billion to US\$108.1 billion, growing at a CAGR of 6.3%, and will remain the largest in absolute terms.

Global In Vitro Diagnostics (IVD) Market Size and Forecast, Breakdown by Region, 2020-2035E

Unit: Billion USD
At ex-factory price level

Period	CAGR						Total
	China	North America	Latin America	EU5 ⁽¹⁾	Asia Pacific	RoW	
2020-2024	7.6%	3.5%	5.8%	3.0%	5.3%	0.3%	4.2%
2025-2030E	8.6%	6.4%	9.1%	6.1%	8.3%	0.9%	6.9%
2031E-2035E	10.9%	5.2%	9.6%	4.5%	8.5%	8.4%	7.1%



INDUSTRY OVERVIEW

1. *Comprising of Germany, Italy, France, the United Kingdom, and Spain.*

Note: The CAGR calculated here excludes the impact of exchange rate fluctuations. Developed markets include North America and EU5; emerging markets include Latin America, Asia Pacific and RoW. China is presented separately.

Source: Frost & Sullivan Analysis

From 2020 to 2024, the China market expanded from RMB99.2 billion to RMB133.1 billion at a CAGR of 7.6% but with clear swings. The market is expected to reach RMB199.0 billion in 2030 at a CAGR of 8.6% between 2025 and 2030, and further to RMB336.4 billion in 2035 at a CAGR of 10.9% between 2031 and 2035.

Competitive Landscape

The following tables sets forth the competitive landscape of the IVD market globally and in China in terms of revenue in 2024.

Competitive Landscape of Global IVD Market in Terms of Revenue, 2024

Rank	Company ⁽¹⁾	Revenue <i>(USD in Billion)</i>	Market Share <i>(%)</i>
1	Company C	16.3	12.8%
2	Company E	9.8	7.7%
3	Company F	9.3	7.4%
4	Company D	4.8	3.8%
5	Company G	4.5	3.6%

Note:

(1) Company E is a global science and technology company focused on life sciences, diagnostics, and environmental solutions, which is headquartered in the United States and listed on the New York Stock Exchange.

Company F is a multinational company headquartered in the United States that engages in discovery, development, manufacture, and sale of a broad and diversified line of healthcare products and listed on the New York Stock Exchange and Chicago Stock Exchange, Inc.

Company G is a life science and clinical research company headquartered in the United States that provides analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services, and listed on the New York Stock Exchange.

Competitive Landscape of China’s IVD Market in Terms of Revenue, 2024

Rank	Company ⁽¹⁾	Revenue <i>(RMB in Billion)</i>	Market Share <i>(%)</i>
1	Company C	19.6	14.7%
2	Mindray	9.1	6.9%
3	Company E	7.4	5.6%
4	Company H	5.9	4.5%
5	Company I	5.0	3.7%

Note:

(1) Company H is a division of a multinational medical device and healthcare company headquartered in the United States and listed on the New York Stock Exchange, providing a vast range of testing solutions for core labs, molecular, and point-of-care settings.

Company I is a multinational company headquartered in Japan that engages in the development, manufacture, import, export, and sale of clinical laboratory instruments, reagents, and software used in in-vitro diagnostics.

INDUSTRY OVERVIEW

The IVD industry comprises several core segments based on different detection principles and methodologies, including biochemistry diagnosis, immunodiagnosics, molecular diagnostics, hematology, coagulation, point-of-care testing (POCT) and other diagnostics including microbiology.

The global chemiluminescence immunoassay market represented an addressable market of US\$22.1 billion in 2024, with the top three players accounting for the majority of the market share. The chemiluminescence immunoassay market in China represented an addressable market of RMB38.2 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 3 in the chemiluminescence immunoassay market in China in 2024.

The global hematology testing market represented an addressable market of US\$3.9 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 2 in the global hematology testing market in 2024. The hematology testing market in China represented an addressable market of RMB6.7 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 1 in the hematology testing market in China in 2024.

The global biochemistry diagnostics market represented an addressable market of US\$13.3 billion in 2024. The biochemistry diagnostics market in China represented an addressable market of RMB12.0 billion in 2024. The Company ranked No.1 in the biochemistry diagnostics market in China in 2024.

Growth Drivers and Future Trends

- **Technological Advancement:** The IVD industry continues to evolve toward higher throughput, faster turnaround time and greater precision, while laboratory automation and integrated solutions are improving efficiency, reducing manual intervention by up to 80% and enhancing data traceability.
- **Healthcare System Expansion and Upgrade:** Growth is supported by healthcare infrastructure expansion, particularly in emerging markets, and by the shift of testing closer to patients, which is driving broader adoption of biochemistry, immunoassay and point-of-care testing (POCT) systems.
- **Domestic Substitution:** In China, local players are narrowing the technology gap with global leaders through improving product performance, stronger cost competitiveness and broader service networks, with domestic high-speed chemiluminescence immunoassay (CLIA) systems exceeding 900 tests per hour.
- **Impact of Healthcare Policies:** In China, volume-based procurement and diagnosis-related groups/diagnosis-intervention packet (DRG/DIP) reforms are increasing pricing pressure while accelerating domestic substitution and favoring companies with scale, cost competitiveness and reliable supply.

The IVD industry continues to face challenges in assay consistency, clinical validation, workflow integration and quality control, while price pressure, platform consolidation and the shift toward near-patient and home testing continue to increase competitive intensity and entry barriers.

INDUSTRY OVERVIEW

THE PATIENT MONITORING AND LIFE SUPPORT MARKET


Overview

The global PMLS market is expected to experience steady growth. The market increased from US\$9.7 billion in 2020 to US\$11.9 billion in 2024, representing a CAGR of 5.2% between 2020 and 2024, and is projected to reach US\$15.2 billion in 2030 at a CAGR of 4.4% between 2025 and 2030, and further to US\$17.5 billion in 2035 at a CAGR of 2.6% between 2031 and 2035. Emerging markets are expected to grow two to three times faster than developed markets, driven by accelerated healthcare infrastructure investment and expanding access to care. From 2025 to 2030, emerging markets are expected to rise from US\$3.5 billion to US\$6.0 billion, growing at a CAGR of 11.3%, representing robust momentum and a major source of incremental demand. From 2025 to 2030, developed markets are expected to expand from US\$7.5 billion to US\$7.9 billion, growing at a CAGR of 1.3%, remaining the largest in absolute terms but with subdued growth.

Global Patient Monitoring & Life Support Market Size and Forecast, Breakdown by Region, 2020-2035E

Unit: Billion USD
At ex-factory price level

Period	CAGR					RoW	Total
	China	North America	Latin America	EU5 ¹⁾	Asia Pacific		
2020-2024	-11.1%	7.2%	25.3%	6.9%	22.9%	9.1%	5.2%
2025-2030E	-0.2%	1.4%	13.2%	1.1%	15.8%	-0.9%	4.4%
2031E-2035E	4.2%	0.6%	4.3%	0.5%	5.1%	5.1%	2.6%



1. Comprising of Germany, Italy, France, the United Kingdom, and Spain.

Note: The CAGR calculated here excludes the impact of exchange rate fluctuations. Developed markets include North America and EU5; emerging markets include Latin America, Asia Pacific and RoW. China is presented separately.

Source: Frost & Sullivan Analysis

The PMLS market in China change from RMB18.5 billion in 2020 to RMB11.5 billion in 2024, representing a CAGR of -11.1% between 2020 and 2024; the decline reflects (2022) an ICU “urgent procurement” spike during reopening that inflated the base for ventilators, monitors and infusion stations, (2023) a partial unwind with destocking and slower elective-surgery recovery that deferred anesthesia-machine renewals, and (2024) a sharper downturn as anti-corruption tightened approvals, hospital projects and budgets were delayed, DRG/DIP and the sunset of COVID earmarks constrained capex, and VBP plus fast domestic substitution compressed ASPs, especially in monitors and infusion. From 2025 to 2027, the market will continue to decline due to China PMLS market’s heavy reliance on government budgets. Tightened budgets will lead to minimal growth in new ICU bed capacity, with growth driven primarily by equipment replacement in existing ICUs. The market is projected to reach RMB9.3 billion in 2030, and further to RMB11.6 billion in 2035 at a CAGR of 4.2% between 2031 and 2035.

INDUSTRY OVERVIEW

Competitive Landscape

The following tables sets forth the competitive landscape of the patient monitoring and life support market globally and in China in terms of revenue in 2024.

Competitive Landscape of Global Patient Monitoring and Life Support Market in Terms of Revenue, 2024

Rank	Company ⁽¹⁾	Revenue <i>(USD in Billion)</i>	Market Share <i>(%)</i>
1	Mindray	1.7	14.3%
2	Company J	1.7	13.9%
3	Company K	1.6	13.4%
4	Company L	1.0	8.4%
5	Company M	0.9	7.7%

Note:

(1) Company J is a multinational company headquartered in the United States that is a leading global healthcare solutions provider and listed on the NASDAQ, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics.

Company K is a multinational health technology company headquartered in Netherlands that develops and manufactures medical devices in hospital patient monitoring, diagnostic imaging and enterprise informatics and listed on the New York Stock Exchange.

Company L is a leading international company headquartered in Germany that develops, manufactures, and sells devices and systems in the fields of medical and safety technology and listed on the Frankfurt Stock Exchange.

Company M is a leading manufacturer, developer and distributor of medical electronic equipment headquartered in Japan and listed on the Tokyo Stock Exchange.

Competitive Landscape of China’s Patient Monitoring and Life Support Market in Terms of Revenue, 2024

Rank	Company	Revenue <i>(RMB in Billion)</i>	Market Share <i>(%)</i>
1	Mindray	5.1	44.4%
2	Company L	1.3	10.8%
3	Company N	1.2	10.6%
4	Company J	0.9	7.4%
5	Company O	0.6	4.8%

Note:

(1) Company N is a global medical equipment manufacturer specializing in patient monitoring, NICU and ICU solutions headquartered in China.

Company O is a global healthcare company manufacturing patient monitors, diagnostic ECGs, ultrasounds, and other medical equipment headquartered in China.

The global patient monitor market represented an addressable market of US\$4.0 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 2 in the global patient monitor market in 2024. The patient monitor market in China represented an addressable market of RMB3.5 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 1 in the patient monitor market in China in 2024.

INDUSTRY OVERVIEW

The global anesthesia system market represented an addressable market of US\$2.1 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 3 in the global anesthesia system market in 2024. The anesthesia system market in China represented an addressable market of RMB2.0 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 1 in the anesthesia system market in China in 2024.

The global ventilator market represented an addressable market of US\$1.8 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 3 in the global ventilator market in 2024. The ventilator market in China represented an addressable market of RMB2.4 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 1 in the ventilator market in China in 2024.

The global defibrillator market represented an addressable market of US\$1.2 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 3 in the global defibrillator market in 2024. The defibrillator market in China represented an addressable market of RMB1.2 billion in 2024, with the top three players accounting for the majority of the market share. The Company ranked No. 1 in the defibrillator market in China in 2024.

Growth Drivers and Future Trends

- ***Rise of Intelligent Integrated Ecosystems:*** Critical care devices are increasingly shifting from standalone products to connected ecosystems integrated with hospital IT systems and embedded analytics.
- ***Shift to Service-Oriented Value-Based Procurement:*** Procurement is increasingly focused on total cost of ownership, uptime, cybersecurity and measurable outcomes, rather than one-time device purchases alone.
- ***Flexible Deployment and Resilient Supply Chains:*** Demand for portable and modular devices continues to grow across broader care settings, while localized supply and service capabilities are becoming more important.

The PMLS industry continues to face challenges in ensuring continuous performance, signal reliability, alarm management, cybersecurity, hospital IT integration and service continuity, while procurement teams are placing greater emphasis on measurable outcomes and existing players benefit from entrenched service networks, training systems and installed-base advantages.

THE MEDICAL IMAGING MARKET

Overview

Medical imaging refers to a range of technologies used to visualize the internal structures and functions of the human body for disease prevention, screening, diagnosis, treatment planning and efficacy assessment.


The global medical imaging market is a significant and growing segment of the healthcare industry. From 2020 to 2024, the global medical imaging market rose from US\$63.8 billion to US\$87.2 billion at a CAGR of 8.2% between 2020 and 2024, and is projected to reach US\$120.6 billion in 2030 at a CAGR of 5.7% between 2025 and 2030, and further to US\$154.3 billion in 2035 at a CAGR of 4.9% between 2031 and 2035. From 2025 to 2030, developed markets expand from US\$54.5 billion to US\$66.9 billion, growing at a CAGR of 4.2%, and will continue to account for the largest share in absolute terms. From 2025 to 2030, emerging markets rise from US\$23.7 billion to US\$34.7 billion, growing at a CAGR of 7.9%, the fastest among regions and a primary source of incremental demand in medical imaging.

INDUSTRY OVERVIEW

In developed markets such as the United States and Europe, growth in medical imaging is primarily driven by replacement demand for high-value equipment and adoption of advanced technologies, including AI-assisted diagnosis, multi-modal image fusion and intelligent workflow solutions, supported by demand for greater operational efficiency, diagnostic precision and high-performance devices for chronic disease management. In emerging markets, growth is mainly supported by healthcare infrastructure expansion and public procurement, driving demand for cost-effective products such as digital radiography (DR) and portable ultrasound systems, with durable products and strong local service capabilities remaining important competitive factors. In China, demand continues to be supported by the high prevalence of chronic diseases, policies promoting tiered healthcare and regional imaging centers, and increasing adoption of digital and intelligent applications, while domestic manufacturers continue to strengthen competitiveness in segments such as ultrasound and DR and gradually expand into higher-end markets.

Global Medical Imaging Market Size and Forecast, Breakdown by Region, 2020-2035E

Unit: Billion USD
At ex-factory price level



1. Comprising of Germany, Italy, France, the United Kingdom, and Spain.

Note: The CAGR calculated here excludes the impact of exchange rate fluctuations. Developed markets include North America and EU5; emerging markets include Latin America, Asia Pacific and RoW. China is presented separately.

Source: Frost & Sullivan Analysis

China medical imaging declined from RMB95.0 billion in 2020 to RMB90.5 billion in 2024 (CAGR -1.2%) for sector-specific reasons: 2020-2022 saw a one-off CT/DR surge for fever-clinic screening while heavy-install MR/PET-CT upgrades were postponed by site renovation, shielding and acceptance constraints; 2023 brought normalization and destocking, softer private check-up demand and lower utilization that deferred replacements; in 2024, targeted anti-corruption in radiology/contrast procurement, DRG/DIP test-volume discipline, and aggressive provincial tenders plus rapid domestic competition compressed ASPs, especially in ultrasound/DR. The market is projected to reach RMB137.4 billion in 2030 at a CAGR of 7.4% between 2025 and 2030, and further to RMB182.8 billion in 2035 at a CAGR of 5.7% between 2031 and 2035.

INDUSTRY OVERVIEW

Competitive Landscape

The ultrasound system market features high concentration globally and domestically. In 2024, the top three global players accounted for the majority of the market share, where the Company ranked third. In the same year, the top three players in the ultrasound system market in China totally accounted for the majority of the market share, where the Company ranked first. We also maintained leading positions in the sub-markets of trolley-based ultrasound system, portable ultrasound system and handheld ultrasound diagnostic device globally.

Growth Drivers and Future Trends

- ***Integration of AI-Driven Imaging Intelligence:*** Growth continues to be supported by replacement demand for advanced imaging equipment, with AI increasingly embedded into imaging systems to improve accuracy, efficiency and workflow automation.
- ***Expanding Access Through Portable Systems and Infrastructure Growth:*** Growth is also supported by broader healthcare infrastructure buildout and increasing adoption of portable and compact imaging systems, which are expanding diagnostic access in primary care, emergency and lower-tier settings.
- ***Shift to Value-Based Procurement and Cloud-Enabled Service Models:*** Procurement is increasingly focused on total cost of ownership, clinical validation and service reliability, while cloud platforms, teleradiology and predictive maintenance are supporting more service-oriented and flexible deployment models.

Medical imaging is shaped by capital intensity, infrastructure readiness, and enterprise integration complexity. Adoption depends not only on image quality but also on facility preparedness, trained staff, throughput, and governance of radiation dose and protocols, while interoperability gaps in multi-vendor environments persist despite DICOM standards. Commercial risks include utilization controls by payers and health systems, cyber downtime that can halt scanners or imaging networks, and rapid feature commoditization that erodes differentiation unless vendors demonstrate measurable gains in throughput, diagnostic confidence, or total workflow cost. Entry barriers are structurally high: vendors require substantial engineering scale, specialized supply chains, strong field service, deep integration capabilities, access to large labeled datasets for AI, performance governance, financing options, and credible reference sites — factors that favor incumbents with scale and long track records.

THE MINIMALLY INVASIVE SURGERY MARKET

Overview

Minimally invasive surgery refers to surgical procedures performed through small incisions, which generally reduce patient trauma, pain and recovery time compared with open surgery.

The global minimally invasive surgery market is a large and rapidly growing segment, driven by the clinical shift away from open surgery. The global minimally invasive surgery market has maintained steady expansion, increasing from US\$27.7 billion in 2020 to US\$33.8 billion in 2024 with a CAGR of 5.1% between 2020 and 2024, and is projected to grow to US\$52.5 billion in 2030 with a CAGR of 8.2% between 2025 and 2030, and further to US\$83.9 billion in 2035 at a CAGR of 9.6% between 2031 and 2035. North America accounts for over 40% of the market, supported by technological leadership and a large installed base. The fastest growth is projected in Latin America, with China also exhibiting strong momentum and serving as the principal growth engine.


Developed markets accounted for approximately 68.8% of the market in 2024, while emerging markets are projected to outgrow at a 12.2% CAGR between 2025 and 2030, and China is projected to grow at a 11.5% CAGR during the same period.

INDUSTRY OVERVIEW

Global Minimally Invasive Surgery Market Size and Forecast, Breakdown by Region, 2020-2035E

Unit: Billion USD
At ex-factory price level

Period	CAGR						Total
	China	North America	Latin America	EU5 ¹⁾	Asia Pacific	RoW	
2020-2024	7.9%	4.0%	10.9%	3.9%	10.8%	1.6%	5.1%
2025-2030E	11.5%	6.4%	14.2%	5.9%	12.1%	0.4%	8.2%
2031E-2035E	11.6%	7.2%	15.3%	7.1%	13.6%	8.2%	9.6%



1. Comprising of Germany, Italy, France, the United Kingdom, and Spain.

Note: The CAGR calculated here excludes the impact of exchange rate fluctuations. Developed markets include North America and EU5; emerging markets include Latin America, Asia Pacific and RoW. China is presented separately.

Source: Frost & Sullivan Analysis

The minimally invasive surgery market in China increased from RMB27.6 billion in 2020 to RMB37.3 billion in 2024 with a CAGR of 7.9% between 2020 and 2024, and is projected to grow to RMB69.2 billion in 2030 with a CAGR of 11.5% between 2025 and 2030, and further to RMB120.6 billion in 2035 at a CAGR of 11.6% between 2031 and 2035.

Growth Drivers and Future Trends

- Global Expansion:** Overseas markets are becoming an important growth driver for Chinese minimally invasive surgery companies, particularly in Europe and the United States, where mature reimbursement systems and higher procedure pricing support market expansion. Chinese companies are improving international competitiveness through faster CE/FDA certification, channel upgrading from OEM to own-brand distribution, and stronger local service capabilities.
- Intelli-digitalization Breakthrough:** Continuous breakthroughs in AI and material science are broadening the scope of clinical applications. Surgical robotic systems are driving steady expansion in the high-end market. Their 3D vision systems and tremor-filtering technology help lower learning requirements for complex procedures, enabling more standardized adoption in lower-tier hospitals.

Minimally invasive surgery must deliver consistent outcomes within tightly scheduled operating theatre workflows, requiring standardized techniques beyond individual expert operators and reliable integration across increasingly complex device ecosystems spanning visualization, energy platforms, stapling, and robotics. Practical constraints such as sterilization capacity, disposable supply planning, and procurement scrutiny — alongside demands for real-world evidence of complication reduction and efficiency gains — shape adoption. Commercial threats stem from cost pressure, value analysis processes, safety perception, and intense platform competition, particularly when premium pricing lacks clear proof of improved outcomes or lower total episode cost, while incumbents bundle instruments, service, and training to consolidate share.

INDUSTRY OVERVIEW

Entry barriers are reinforced by training ecosystems, installed base, and switching costs: new entrants must invest in surgeon education, proctoring networks, and clinical support, pass formulary and value reviews, and navigate dense intellectual property and accessory compatibility requirements, all of which favor scaled incumbents.

THE MINIMALLY INVASIVE INTERVENTION MARKET

Overview

Minimally invasive interventions (“MII”) refer to diagnostic and therapeutic procedures performed through vascular or natural pathways under imaging guidance, typically involving high-value, single-use medical consumables.


The global endovascular intervention device market increased from USD30.7 billion in 2020 to USD41.8 billion in 2024, representing a CAGR of 8.0%, and is expected to grow at CAGRs of 6.7% from 2025 to 2030 and 4.5% from 2031 to 2035. Growth is driven by population ageing, rising prevalence of peripheral arterial and venous thromboembolic diseases, and continued replacement of open surgery by stent grafts, drug-eluting balloons, thrombectomy systems and other catheter-based solutions, while pricing pressure and high penetration in developed markets are expected to gradually moderate growth in the long term.

The global market size of electrophysiology medical device rose from US\$5.8 billion in 2020 to US\$12.0 billion in 2024 at a CAGR of 20.1%, and is projected to reach US\$28.0 billion in 2030 at a CAGR of 14.7% between 2025 and 2030, and further to US\$46.0 billion in 2035 at a CAGR of 10.1% between 2031 and 2035.

In 2024, the global minimally invasive intervention market was primarily composed of endovascular intervention, which accounted for approximately 77.7%, while electrophysiology accounted for approximately 22.3%.

Global Minimally Invasive Intervention Market Size and Forecast, Breakdown by Product Type, 2020-2035E

Unit: Billion USD
At ex-factory price level



Source: Frost & Sullivan Analysis

In China, the endovascular intervention device market expanded from RMB27.5 billion in 2020 to RMB43.0 billion in 2024, representing a CAGR of 11.9%, and is forecast to grow at CAGRs of 10.5% from 2025 to 2030 and 9.5% from 2031 to 2035. Market growth is supported by accelerating build-out of vascular intervention capability in tertiary and secondary hospitals, increasing procedure volumes for peripheral arterial disease, aortic and neurovascular interventions, and ongoing import substitution by competitive domestic products, partly offset by volume-based procurement and DRG/DIP-driven reimbursement constraints on unit pricing.


INDUSTRY OVERVIEW

The China market size of electrophysiology medical device rose from RMB5.2 billion in 2020 to RMB11.8 billion in 2024 at a CAGR of 23.1% between 2020 and 2024, and is projected to reach RMB33.1 billion in 2030 at a CAGR of 18.2% between 2025 and 2030, and further to RMB60.9 billion in 2035 at a CAGR of 12.4% between 2031 and 2035.

In 2024, the China minimally invasive intervention market was primarily composed of endovascular intervention, which accounted for approximately 78.3%, while electrophysiology accounted for approximately 21.5%.

China Minimally Invasive Intervention Market Size and Forecast, Breakdown by Product Type, 2020-2035E


Unit: Billion RMB
At ex-factory price level



Source: Frost & Sullivan Analysis

Global Minimally Invasive Intervention Market Size and Forecast, Breakdown by Region, 2020-2035E

Unit: Billion USD
At ex-factory price level



Source: Frost & Sullivan Analysis

INDUSTRY OVERVIEW

Developed markets accounted for approximately 56.4% of the global market in 2024, while emerging markets are projected to outgrow at a CAGR of 10.8% between 2025 and 2030, and China is projected to grow at a CAGR of 12.5%.

Growth Drivers and Future Trends

Technological and product innovation continues to support localization in the minimally invasive intervention market, as domestic products improve in performance, compatibility and cost efficiency and progressively substitute imported brands. At the same time, technologies such as 3D mapping and navigation, pulsed-field ablation, and drug-eluting and bioresorbable materials are expanding clinical applications. Recent market trends are also driving prices toward more rational levels while favoring high-quality and compliant suppliers, with hospitals increasingly adopting procurement models integrating implants, procedural kits and technical support. In addition, localized manufacturing and after-sales service networks continue to enhance cost efficiency and supply reliability.

Across regions, market growth dynamics vary. In developed markets such as the United States and Western Europe, growth is mainly driven by replacement demand and adoption of next-generation electrophysiology and structural heart technologies, with clinical validation, long-term safety and brand credibility remaining key purchasing criteria. In emerging markets, healthcare infrastructure expansion and government-backed procurement are supporting adoption of interventional devices, particularly products combining clinical reliability, cost efficiency and localized service support. In China, growth is supported by the high prevalence of cardiovascular and cerebrovascular diseases, continued development of regional medical centers and upgrading of catheterization laboratories and hybrid operating rooms, while improving domestic product performance and cost competitiveness continue to accelerate domestic substitution.

Interventional cardiology, peripheral intervention, and electrophysiology are outcomes-driven and fast-moving markets where success depends on generating credible clinical evidence with meaningful follow-up, ensuring deliverability in complex anatomy, and integrating seamlessly with imaging, guidewire, and mapping ecosystems. Performance is highly operator-dependent, requiring sustained investment in training, proctoring, and case support, while broad product portfolios create inventory complexity and adoption remains sensitive to reimbursement and catheter lab budgets, demanding clear linkage to measurable clinical and operational endpoints. Commercial risks include price compression through tenders and value-based procurement, rapid technology substitution that can strand legacy inventories, and post-market safety signals that may trigger swift guideline and purchasing shifts, amplifying volatility. Entry barriers combine advanced manufacturing control over specialty materials and sterilization at scale with physician trust, reference sites, hospital contracting leverage, and the need for global training and service networks — factors that favor vendors with scale, broad portfolios, and established field support.

THE ANIMAL MEDICAL DEVICE MARKET

Overview

The animal medical device market covers products used for the prevention, diagnosis, treatment and health management of diseases in companion animals and livestock. By product category, the market primarily includes PMLS products, IVD products and medical imaging products, such as veterinary anesthesia systems and monitors, hematology and biochemistry diagnostic devices, immunodiagnostic and urinalysis products, and imaging systems including ultrasound and DR.

From 2020 to 2024, it expanded from US\$3.6 billion to US\$4.4 billion at a CAGR of 5.3%. From 2025 to 2030, it is projected to reach US\$7.0 billion at a CAGR of 8.7%, as veterinary hospitals scale imaging, anesthesia, monitoring, and therapeutics. From 2031 to 2035, growth moderates to US\$11.3 billion at a CAGR of 9.8%, reflecting a higher base and more mature

INDUSTRY OVERVIEW


penetration yet continued upgrades of equipment and services. Developed markets accounted for approximately 75.1% of the global market in 2024, while emerging markets are projected to outgrow at a CAGR of 10.4% between 2025 and 2030, and China is projected to grow at a CAGR of 9.8%.

In developed markets such as the United States and Europe, demand for veterinary devices is generally characterized by stable, high-value procurement, supported by factors such as high pet insurance penetration, stricter animal welfare standards and rising demand for advanced veterinary care, which together drive replacement demand for high-performance systems in animal hospitals and clinic chains. In emerging markets, rapid growth of the pet economy and the early-stage development of veterinary healthcare are supporting demand for essential devices such as ultrasound systems, monitors, anesthesia systems and basic diagnostic instruments, with durable, easy-to-maintain and cost-effective products being more competitive. In China, rising pet ownership, consumption upgrading and expansion of animal hospitals and clinic chains continue to support demand for imaging, monitoring, anesthesia and diagnostic devices, while domestic brands are strengthening competitiveness through cost efficiency, localization and after-sales service advantages.

Global Animal Medical Device Market Size and Forecast, Breakdown by Region, 2020-2035E

Unit: Billion USD
At ex-factory price level

Period	CAGR						Total
	China	North America	Latin America	EU5 ¹⁾	Asia Pacific	RoW	
2020-2024	2.8%	5.4%	8.5%	5.1%	7.6%	4.3%	5.3%
2025-2030E	9.8%	8.4%	11.9%	7.9%	11.0%	7.3%	8.7%
2031-2035E	10.6%	9.1%	14.1%	8.6%	13.4%	9.5%	9.8%



1. Comprising of Germany, Italy, France, the United Kingdom, and Spain.

Note: The CAGR calculated here excludes the impact of exchange rate fluctuations. Developed markets include North America and EU5; emerging markets include Latin America, Asia Pacific and RoW. China is presented separately.

Source: Frost & Sullivan Analysis

China’s animal medical device market expanded from RMB 2.2 billion in 2020 to RMB 2.4 billion in 2024, representing a CAGR of 2.8%. The market is expected to reach RMB 4.2 billion in 2030, at a CAGR of 9.8% from 2025 to 2030, and is expected to further increase to RMB 6.9 billion in 2035, at a CAGR of 10.6% from 2031 to 2035.

INDUSTRY OVERVIEW

Growth Drivers and Future Trends

- ***Rising Pet Ownership and Consumption Upgrading.*** The global companion animal population continues to expand, supported by social and demographic trends. Higher disposable income and lifestyle changes have increased willingness to pay for preventive and advanced medical care.
- ***Advancing Veterinary Infrastructure.*** Upgrading of animal hospitals, expansion of chain clinics, and wider adoption of diagnostic and monitoring technologies are broadening access to quality veterinary services, particularly in emerging markets.
- ***Localization and Service Networks.*** Local manufacturing and service capabilities are becoming increasingly important to ensure compliance, cost-effectiveness, and faster response times, particularly in markets with fragmented distribution channels.

Animal health devices inherit technical demands from human healthcare but face added complexity from species diversity and fragmented care settings, increasing product variants, validation burden, and workflow variability across small clinics, referral centers, and farm or field environments. Evidence generation is harder to scale, reimbursement is uneven, and demand is sensitive to discretionary spending and owner out-of-pocket payments, while fragmented channels can invite uneven quality competition and supply fragility that heightens downtime risk. Entry barriers are primarily commercial: scaling requires dense distribution and service coverage, trusted reference clinics, responsive after-sales support, and products that are rugged and easy to use in resource-constrained settings, with profitability further challenged by lower volumes that demand disciplined manufacturing and inventory management to sustain reliable service.

MEDICAL INTELLI-DIGITALIZATION AND AI DEVELOPMENT

Evolution of Intelli-digitalization in the Medical Device Industry

From a macro-industrial perspective, the intelli-digital transformation of the medical device industry has progressed from early digitalization, which converted analog devices into digital data carriers, to data interconnection enabled by mobile internet and the Internet of Things, and further to the current stage of comprehensive intelligigital integration driven by artificial intelligence, big data and 5G technologies. At present, intelli-digitalization is extending from device-level functions to end-to-end integration across research and development, manufacturing, clinical application and after-sales service, and is increasingly reshaping productivity and operating models across the medical device industry.

Applications of Intelli-digitalization

Intelli-digital applications in healthcare are accelerating across hospital operations, clinical practice and patient management, improving efficiency, diagnostic accuracy and accessibility.

Key Growth Drivers

The ongoing development of medical intelli-digitalization is shaped by several key technological and structural drivers.

- ***Expansion of Clinical Data Exchange:*** Growth in electronic health records, connected devices and real-world data is increasing demand for standardized data sharing and interoperable systems, with hospitals linking PACS, LIS, HIS and cloud platforms to support real-time analytics, remote monitoring and longitudinal patient management.

INDUSTRY OVERVIEW

- **Development of AI Technologies:** AI is increasingly integrated into imaging, diagnostic and therapeutic devices to improve accuracy, reduce clinician workload and support precision medicine through applications such as image recognition, predictive analytics, anomaly detection and robotic surgery planning, while newer architectures are moving toward privacy-preserving and multimodal models.
- **Integration of Medical Insurance:** Remote monitoring devices and wearable or implantable sensors are increasingly being integrated with reimbursement and payment models, as payers and providers place greater emphasis on early risk detection, proactive intervention and value-based chronic disease management.

Medical devices are evolving toward advanced, privacy-preserving AI architectures that enable continuous learning from distributed data through federated learning, multimodal models (images, signals, text), and adaptive algorithms, improving diagnostic accuracy and workflow without centralizing patient data. Manufacturers are embedding edge processors and low-latency AI chips into imaging, monitoring, and interventional systems to deliver real-time, on-device insights with reduced cloud dependence, supporting use in bandwidth-constrained settings. At the same time, digitalized platforms are connecting hardware, middleware, and clinical IT into secure cloud ecosystems that enable remote updates, predictive maintenance, cross-site collaboration, and subscription or outcome-based models, with leading multinational vendors increasing R&D investment to scale these integrated, cybersecurity-enabled solutions.

Medical intelligence and digitalization hinge on interoperability, data rights, and workflow integration — not just algorithm performance — requiring standards-based exchange (e.g., HL7 FHIR), prospective validation, explainability, drift monitoring, and secure update processes, while privacy and security constraints limit cross-site learning and raise maintenance costs. Risks concentrate around governance, safety, and cybersecurity, with stricter regulatory regimes (such as the EU AI Act) imposing high-risk controls, transparency, and human oversight requirements; safety incidents or cyberattacks can quickly erode clinician trust, disrupt deployments, and increase liability. The strongest entry barriers are access to large, legally usable datasets, deep integration with EHRs and device fleets, and distribution scale, as interoperability implementation is resource-intensive and creates switching costs; incumbents benefit from platform network effects, forcing challengers to demonstrate not only superior models but also lower migration risk and clearly quantified operational value.

SOURCE OF INFORMATION AND RESEARCH METHODOLOGY

The information and statistics set out in this section and other sections of this Document were extracted from different official government publications, available sources from public market research and other sources from independent suppliers. In addition, we engaged Frost & Sullivan for preparing an independent industry report in respect of the [REDACTED]. The information from Frost & Sullivan disclosed in the Document is extracted from the Frost & Sullivan Report, a report commissioned by us for a fee of RMB950,000, and is disclosed with the consent of Frost & Sullivan. The Frost & Sullivan Report has been prepared by Frost & Sullivan independently without any influence from us or other interested parties.

Frost & Sullivan is an independent global consulting firm founded in 1961 in New York and its services include, among others, industry consulting, market strategic consulting and corporate training. Frost & Sullivan conducted (i) primary research, which involved discussing the status of the industry with certain leading industry participants, and interviews with industry experts on a best-effort basis to collect information in aiding in-depth analysis; and (ii) secondary research, which involved reviewing company reports, independent research reports and data based on its own research database.

Except as otherwise noted, all of the data and forecasts contained in this section are derived from the Frost & Sullivan Report. Our Directors confirm that after taking reasonable care, there is no material adverse change in the overall market information since the date of the Frost & Sullivan Report that would materially qualify, contradict or have an impact on such information.